Why Public Health Agencies Cannot Depend on Good Laboratory Practices as a Criterion for Selecting Data: The Case of Bisphenol A

MOspace/Manakin Repository

Breadcrumbs Navigation

Why Public Health Agencies Cannot Depend on Good Laboratory Practices as a Criterion for Selecting Data: The Case of Bisphenol A

Please use this identifier to cite or link to this item: http://hdl.handle.net/10355/10161

[+] show full item record


Title: Why Public Health Agencies Cannot Depend on Good Laboratory Practices as a Criterion for Selecting Data: The Case of Bisphenol A
Author: Myers, John Peterson; vom Saal, Frederick S.; Akingbemi, Benson T.; Arizono, Koji; Belcher, Scott; Colborn, Theo; Chahoud, Ibrahim; Crain, D. Andrew, 1970-; Farabollini, Francesca; Guillette, Louis J., 1954-; Hassold, Terry J.; Ho, Shuk-mei; Hunt, Patricia A.; Iguchi, Taisen, 1951-; Jobling, Susan; Kanno, Jun; Laufer, Hans, 1929-; Marcus, Michele; McLachlan, John A.; Nadal, Angel; Oehlmann, Jörg; Olea, Nicolás; Palanza, Paola; Parmigiani, Stefano; Rubin, Beverly S.; Schoenfelder, Gilbert; Sonnenschein, C. (Carlos); Soto, A. M. (Ana M.); Talsness, Chris E.; Taylor, Julia A.; Vandenberg, Laura N.; Vandenbergh, John G.; Vogel, Sarah; Watson, Cheryl S., 1950-; Welshons, Wade V.; Zoeller, R. Thomas
Keywords: environmental chemicals
chemical hazards
laboratory practices
Good Laboratory Practices
industry sponsored laboratories
Date: 2009-03
Publisher: National Institute of Environmental Health Sciences
Citation: Myers JP, vom Saal FS, Akingbemi BT, Arizono K, Belcher S, et al. 2008 Why Public Health Agencies Cannot Depend on Good Laboratory Practices as a Criterion for Selecting Data: The Case of Bisphenol A. Environmental Health Perspectives 117(3).
Abstract: We reviewed differences between industry-funded GLP studies of BPA conducted by commercial laboratories for regulatory purposes and non-GLP studies conducted in academic and government laboratories to identify hazards and molecular mechanisms mediating adverse effects. We examined the methods and results in the GLP studies that were pivotal in the draft decision of the U.S. FDA declaring BPA safe in relation to findings from studies that were competitive for U.S. National Institutes of Health (NIH) funding, peer-reviewed for publication in leading journals, subject to independent replication, but rejected by the U.S. FDA for regulatory purposes.
URI: http://hdl.handle.net/10355/10161

This item appears in the following Collection(s)

[+] show full item record